Regeneron, Sanofi slash Praluent list price mirroring Repatha discount
Following Amgen’s decision to slash the price of its cholesterol drug Repatha by 60% to $5,850 last year, the team behind their main rival treatment, Praluent — Regeneron $REGN and Sanofi $SNY — have followed suit with the same discount, beginning early March.
Following approvals in 2015 the two drugs were pegged to attain blockbuster status for their ability to dramatically lower levels of LDL cholesterol, but instead faced pushback from insurers for their high sticker prices that led to lower adoption than expected, despite later trials that demonstrated the PCSK9 inhibitors also significantly cut the risk of heart attacks and stroke. Unlike Repatha, Praluent has also shown to lower the risk of death.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters